Evidence map›Paper›PMID 33729032›Full record

ArticleJournal of diabetes science and technology2022

Rapid Point-of-Care Test for Determination of C-Peptide Levels.

Paturi V Rao, Eric Bean, Dhanalakshmi Nair-Schaef, Siting Chen, Steven C Kazmierczak, Charles T Roberts, Srinivasa R Nagalla

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes science and technology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The evolution of C-peptide's role in diabetes care.Current opinion in endocrinology, diabetes, and obesity · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Paturi V RaoDiabetomics, Inc., Hillsboro, OR, USA.
Eric BeanDiabetomics, Inc., Hillsboro, OR, USA.
Dhanalakshmi Nair-SchaefDiabetomics, Inc., Hillsboro, OR, USA.
Siting ChenSchool of Public Health, Oregon Health & Science University, Portland, OR, USA.
Steven C KazmierczakSchool of Medicine, Oregon Health & Science University, Portland, OR, USA.ORCID 0000-0002-4668-4634
Charles T RobertsDiabetomics, Inc., Hillsboro, OR, USA.ORCID 0000-0003-1756-5772
Srinivasa R NagallaDiabetomics, Inc., Hillsboro, OR, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

C-peptide is co-secreted with insulin and is not subject to hepatic clearance and thus reflects functional β-cell mass. Assessment of C-peptide levels can identify individuals at risk for or with type 1 diabetes with residual β-cell function in whom β cell-sparing interventions can be evaluated, and can aid in distinguishing type 2 diabetes from Latent Autoimmune Diabetes in Adults and late-onset type 1 diabetes. To facilitate C-peptide testing, we describe a quantitative point-of-care C-peptide test. C-peptide levels as low as 0.2 ng/ml were measurable in a fingerstick sample, and the test was accurate over a range of 0.17 to 12.0 ng/ml. This test exhibited a correlation of

Indexed as

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2AdultAutoantibodiesC-PeptideGlutamate DecarboxylaseHumansPoint-of-Care TestingAutoantibodiesC-PeptideGlutamate DecarboxylaseC-peptidediabetesLADAMODYpoint-of-care

Identifiers

PMID33729032
PMCPMC9264426

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.